A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1

A. E. Seif; A. Naranjo; D. L. Baker; N. J. Bunin; M. Kletzel; C. S. Kretschmar; J. M. Maris; P. W. McGrady; D. Von Allmen; S. L. Cohn; W. B. London; J. R. Park; L. R. Diller; S. A. Grupp

doi:10.1038/bmt.2012.276

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1

A. E. Seif, A. Naranjo, D. L. Baker, N. J. Bunin, M. Kletzel, C. S. Kretschmar, J. M. Maris, P. W. McGrady, D. Von Allmen, S. L. Cohn, W. B. London, J. R. Park, L. R. Diller, S. A. Grupp

Biostatistics

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

Increasing treatment intensity has improved outcomes for children with neuroblastoma. We performed a pilot study in the Children's Oncology Group to assess the feasibility and toxicity of a tandem myeloablative regimen without TBI supported by autologous CD34-selected peripheral blood stem cells. Forty-one patients with high-risk neuroblastoma were enrolled; eight patients did not receive any myeloablative consolidation procedure and seven received only one. Two patients out of 41 (4.9%) experienced transplant-related mortality. CD34 selection was discontinued after subjects were enrolled due to serious viral illness. From the time of study enrollment, the overall 3-year EFS and OS were 44.8±9.6% and 59.2±9.2% (N=41). These results demonstrate that tandem transplantation in the cooperative group setting is feasible and support a randomized comparison of single vs tandem myeloablative consolidation with PBSC support for high-risk neuroblastoma.

Original language	English
Pages (from-to)	947-952
Number of pages	6
Journal	Bone Marrow Transplantation
Volume	48
Issue number	7
DOIs	https://doi.org/10.1038/bmt.2012.276
Publication status	Published - Jul 2013

Bibliographical note

Funding Information:
Supported in part by the WW Smith Charitable Trust, and the Foerderer-Murray, Weinberg and Sanford Funds of the Children’s Hospital of Philadelphia (S.A. Grupp); the Robert A. Good/ASBMT New Investigator Award (A.E. Seif); NIH grants U10 CA98413 (COG SDC grant) and U10 CA98543 (COG Chair’s grant). We would also like to thank Danniel Gaidula, MFA, for assistance in preparing Figure 1.

ASJC Scopus Subject Areas

Hematology
Transplantation

Keywords

Pediatric
hematopoietic SCT
neuroblastoma
tandem transplant

Access to Document

10.1038/bmt.2012.276

Cite this

Seif, A. E., Naranjo, A., Baker, D. L., Bunin, N. J., Kletzel, M., Kretschmar, C. S., Maris, J. M., McGrady, P. W., Von Allmen, D., Cohn, S. L., London, W. B., Park, J. R., Diller, L. R., & Grupp, S. A. (2013). A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplantation, 48(7), 947-952. https://doi.org/10.1038/bmt.2012.276

@article{19f874f5eb1d442090ed4570c18544d6,

title = "A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1",

abstract = "Increasing treatment intensity has improved outcomes for children with neuroblastoma. We performed a pilot study in the Children's Oncology Group to assess the feasibility and toxicity of a tandem myeloablative regimen without TBI supported by autologous CD34-selected peripheral blood stem cells. Forty-one patients with high-risk neuroblastoma were enrolled; eight patients did not receive any myeloablative consolidation procedure and seven received only one. Two patients out of 41 (4.9%) experienced transplant-related mortality. CD34 selection was discontinued after subjects were enrolled due to serious viral illness. From the time of study enrollment, the overall 3-year EFS and OS were 44.8±9.6% and 59.2±9.2% (N=41). These results demonstrate that tandem transplantation in the cooperative group setting is feasible and support a randomized comparison of single vs tandem myeloablative consolidation with PBSC support for high-risk neuroblastoma.",

keywords = "Pediatric, hematopoietic SCT, neuroblastoma, tandem transplant",

author = "Seif, {A. E.} and A. Naranjo and Baker, {D. L.} and Bunin, {N. J.} and M. Kletzel and Kretschmar, {C. S.} and Maris, {J. M.} and McGrady, {P. W.} and {Von Allmen}, D. and Cohn, {S. L.} and London, {W. B.} and Park, {J. R.} and Diller, {L. R.} and Grupp, {S. A.}",

note = "Funding Information: Supported in part by the WW Smith Charitable Trust, and the Foerderer-Murray, Weinberg and Sanford Funds of the Children{\textquoteright}s Hospital of Philadelphia (S.A. Grupp); the Robert A. Good/ASBMT New Investigator Award (A.E. Seif); NIH grants U10 CA98413 (COG SDC grant) and U10 CA98543 (COG Chair{\textquoteright}s grant). We would also like to thank Danniel Gaidula, MFA, for assistance in preparing Figure 1.",

year = "2013",

month = jul,

doi = "10.1038/bmt.2012.276",

language = "English",

volume = "48",

pages = "947--952",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "7",

}

Seif, AE, Naranjo, A, Baker, DL, Bunin, NJ, Kletzel, M, Kretschmar, CS, Maris, JM, McGrady, PW, Von Allmen, D, Cohn, SL, London, WB, Park, JR, Diller, LR & Grupp, SA 2013, 'A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1', Bone Marrow Transplantation, vol. 48, no. 7, pp. 947-952. https://doi.org/10.1038/bmt.2012.276

TY - JOUR

T1 - A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma

T2 - Children's Oncology Group study ANBL00P1

AU - Seif, A. E.

AU - Naranjo, A.

AU - Baker, D. L.

AU - Bunin, N. J.

AU - Kletzel, M.

AU - Kretschmar, C. S.

AU - Maris, J. M.

AU - McGrady, P. W.

AU - Von Allmen, D.

AU - Cohn, S. L.

AU - London, W. B.

AU - Park, J. R.

AU - Diller, L. R.

AU - Grupp, S. A.

N1 - Funding Information: Supported in part by the WW Smith Charitable Trust, and the Foerderer-Murray, Weinberg and Sanford Funds of the Children’s Hospital of Philadelphia (S.A. Grupp); the Robert A. Good/ASBMT New Investigator Award (A.E. Seif); NIH grants U10 CA98413 (COG SDC grant) and U10 CA98543 (COG Chair’s grant). We would also like to thank Danniel Gaidula, MFA, for assistance in preparing Figure 1.

PY - 2013/7

Y1 - 2013/7

N2 - Increasing treatment intensity has improved outcomes for children with neuroblastoma. We performed a pilot study in the Children's Oncology Group to assess the feasibility and toxicity of a tandem myeloablative regimen without TBI supported by autologous CD34-selected peripheral blood stem cells. Forty-one patients with high-risk neuroblastoma were enrolled; eight patients did not receive any myeloablative consolidation procedure and seven received only one. Two patients out of 41 (4.9%) experienced transplant-related mortality. CD34 selection was discontinued after subjects were enrolled due to serious viral illness. From the time of study enrollment, the overall 3-year EFS and OS were 44.8±9.6% and 59.2±9.2% (N=41). These results demonstrate that tandem transplantation in the cooperative group setting is feasible and support a randomized comparison of single vs tandem myeloablative consolidation with PBSC support for high-risk neuroblastoma.

AB - Increasing treatment intensity has improved outcomes for children with neuroblastoma. We performed a pilot study in the Children's Oncology Group to assess the feasibility and toxicity of a tandem myeloablative regimen without TBI supported by autologous CD34-selected peripheral blood stem cells. Forty-one patients with high-risk neuroblastoma were enrolled; eight patients did not receive any myeloablative consolidation procedure and seven received only one. Two patients out of 41 (4.9%) experienced transplant-related mortality. CD34 selection was discontinued after subjects were enrolled due to serious viral illness. From the time of study enrollment, the overall 3-year EFS and OS were 44.8±9.6% and 59.2±9.2% (N=41). These results demonstrate that tandem transplantation in the cooperative group setting is feasible and support a randomized comparison of single vs tandem myeloablative consolidation with PBSC support for high-risk neuroblastoma.

KW - Pediatric

KW - hematopoietic SCT

KW - neuroblastoma

KW - tandem transplant

UR - http://www.scopus.com/inward/record.url?scp=84880212028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880212028&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.276

DO - 10.1038/bmt.2012.276

M3 - Article

C2 - 23334272

AN - SCOPUS:84880212028

SN - 0268-3369

VL - 48

SP - 947

EP - 952

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 7

ER -

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this